文献速递流行病学与生物统计基础与转化研究

多访视非劣效性成功概率的协变量调整贝叶斯分层建模扩展

Probability of Success for Establishing Noninferiority Across Multiple Visits: Extension of Covariate-Adjusted Bayesian Hierarchical Modeling Framework.
PubMed 文献 · Stat Med · 2026-01-01

本文提出并研究一种协变量调整的贝叶斯分层建模方法,利用含纵向结局的历史数据定量评估确证性III期试验的成功概率(POS)。该方法可同时满足多个访视的统计与临床界值,并以青光眼眼科项目为例演示其用于Go/No-Go决策框架;模拟评估了试验间异质性、受试者水平方差与访视间相关性的影响。

要点

  • 历史数据借用可缓解招募与伦理难题并提升试验运营效率
  • 多访视纵向结局的POS预测需同时考虑多个访视的非劣效性界值
  • 试验间异质性、受试者水平方差和访视间相关性影响方法操作特性

核心结论

  • 所提协变量调整贝叶斯分层建模方法可定量评估确证性III期试验在多访视非劣效性下的成功概率,并支持Go/No-Go决策。

研究设计与样本

  • 提出并研究一种协变量调整的贝叶斯分层建模方法,利用含纵向结局的历史数据预测未来试验POS。
  • 以青光眼眼科项目为例演示该模型在Go/No-Go决策框架中的应用。
  • 通过模拟评估影响操作特性的关键因素,包括试验间异质性、受试者水平方差和访视间相关性。

主要发现

  • 模拟评估了试验间异质性、受试者水平方差与访视间相关性对方法操作特性的影响。
  • 所提框架可应用于具有相似设置的其他治疗领域研究。

关键数值与推荐

  • 监管机构通常要求针对青光眼的 pivotal III期试验证明相对于标准治疗的非劣效性,可能需同时满足多个访视的统计与临床界值。

临床怎么用

  • 可在POC或II期完成后,用该框架评估III期POS以支持是否推进至确证性试验的决策。

局限性

  • 原文未报告具体样本量、效应量、界值数值或模拟结果的具体数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Effective decision-making plays a vital role throughout the drug development process, particularly when a proof-of-concept (POC) or phase II study has been completed. To determine whether to proceed to a larger-scale, confirmatory phase III study, assessing the uncertainty about the underlying treatment effect and the probability of success (POS) in the phase III study is of critical importance. In this paper, we proposed and investigated a Bayesian covariate-adjusted hierarchical modeling approach leveraging historical data with longitudinal outcome to quantitatively assess the POS of the confirmatory phase III trial. Although historical data borrowing methods are widely used and known for the advantages in alleviating recruitment and ethical challenges as well as improving trial operational efficiency, its application to predicting future trial POS with longitudinal outcome over multiple visits pose methodological challenges. This paper not only provided a comprehensive modeling approach but also demonstrated how the proposed model can be used in a Go/No-Go decision-making framework with a glaucoma eye care project example. For the approval of new drugs targeting glaucoma, regulatory agencies typically require a pivotal phase III trial to demonstrate noninferiority compared to a standard of care treatment. This may involve meeting both statistical and clinical margins across multiple visits simultaneously. Simulations were performed to evaluate the key factors that affect the operating characteristics, such as between-trial heterogeneity, subject-level variance and between-visit correlation. The proposed decision-making framework can also be applied to studies in other therapeutical areas with similar settings.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Zhao Y, Hu Y, Chen X, et al. Probability of Success for Establishing Noninferiority Across Multiple Visits: Extension of Covariate-Adjusted Bayesian Hierarchical Modeling Framework. Stat Med. 2026. PMID: 41665286. doi:10.1002/sim.70423

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。